molecules of the month

“compound 43b”

RBP4 reducer targeting RBP4/TTR PPI

preclinical, in vivo RBP4 reduction

from HTS and optimization

Bioorganic and Medicinal Chemistry

Takeda, Fujisawa, JP

Chemical structure of molecule compound 43b Retinol-binding protein 4 (RBP4)
1 min read

Retinol-binding protein 4 (RBP4) is the sole carrier for retinol (vitamin A). It may also play a role in diabetes and reduction of RBP4 may be beneficial for the ocular disease AMD. Belite Bio had a Ph. III trial ongoing for an oral RBP4 antagonist (LBS-008, tinlarebant) in Stargardt Disease and intends to start a Ph. III trial for AMD in 2022. Stargazer Therapeutics completed a Ph. II study for STG-001 in April. Retinol-bound RBP4 complexes with transthyretin (TTR) to avoid renal clearance, but after release of retinol, apo-RBP4 is excreted by the kidney. Most apo-RBP4 is reabsorbed and degraded. “compound 43b” is proposed to disrupt the RBP4-TTR protein-protein interaction (PPI), reducing blood RBP4 levels in mice at orally doses…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: